Brief: Takeda Pharma Has Halted Joint Development Of Rare Disease Treatment Using Nucleic Acid Technology, Nikkei Says
18/02/2025 10:13
Feb 18 (Reuters) -
* TAKEDA PHARMA HAS HALTED JOINT DEVELOPMENT OF RARE DISEASE
TREATMENT USING NUCLEIC ACID TECHNOLOGY, NIKKEI SAYS
Source text
Further company coverage: 4502.T
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States